Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

Recruiting now · Phase 2

Conditions studied: Hidradenitis Suppurativa (HS)

In brief

The purpose of this study is to evaluate the pharmacokinetics, safety, and efficacy of povorcitinib in adolescent participants with moderate to severe hidradenitis suppurativa over a 54-week open-label treatment period.

Key facts

Study ID

NCT07213973

Run by

Incyte Corporation

People needed

40

Starts

2026-02-02

Expected to finish

2028-03-25

Last updated by the study team

2026-08-06

Who can join

Age: 12 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Aged ≥ 12 to < 18 years at the time of informed consent/assent signing.
• Body weight ≥ 30 kg at both screening and baseline visits.
• Diagnosis of moderate to severe HS for at least 3 months prior to the screening visit.
• Total abscess and inflammatory nodule count of at least 5 at both the screening and baseline visits.
• HS lesions corresponding to refined Hurley Stage IB, IC, IIB, IIC, or III at both the screening and baseline visits.
• Documented history of inadequate response to at least a 3-month course of at least 1 conventional systemic therapy (oral antibiotic or biologic drug) for HS (or demonstrated intolerance to, or have a contraindication to, a conventional systemic therapy for treatment of their HS).
• Agreement to use contraception.
• Willing and able to comply with the study protocol and procedures.
• Further inclusion criteria apply.

You may not qualify if…

• Presence of > 20 draining tunnels (fistulas) at either the screening or baseline visit.
• Women who are pregnant (or who are considering pregnancy) or breastfeeding.
• Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, Q-wave interval abnormalities, current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator.
• Laboratory values outside of the protocol-defined ranges.
• Further exclusion criteria apply.

Where it is running

• Skincare Studio Dermatology Centre — St. John's, Canada (enrolling)
• Medical Dermatology Specialists Phoenix — Phoenix, Arizona, United States (enrolling)
• Saguaro Dermatology — Phoenix, Arizona, United States (enrolling)
• Uconn Health — Farmington, Connecticut, United States (enrolling)
• University of Miami Miller School of Medicine — Miami, Florida, United States (enrolling)
• Skin Research of South Florida, Llc — Miami, Florida, United States (enrolling)
• Trueblue Clinical Research — Tampa, Florida, United States (enrolling)
• Advanced Medical Research Pc — Sandy Springs, Georgia, United States (enrolling)
• Endeavor Health Medical Group — Skokie, Illinois, United States (enrolling)
• Dermatology Skin Cancer Center Leawood — Leawood, Kansas, United States (enrolling)
• Equity Medical — Bowling Green, Kentucky, United States (enrolling)
• Johns Hopkins Univ Schl of Medicine — Baltimore, Maryland, United States (enrolling)
• York Dermatology Center — Richmond Hill, Ontario, Canada (enrolling)
• The Hospital For Sick Children — Toronto, Ontario, Canada (enrolling)
• University of Alabama At Birmingham — Birmingham, Alabama, United States (enrolling)
• Boston Childrens Hospital — Boston, Massachusetts, United States (enrolling)
• Oakland Hills Dermatology Pc — Auburn Hills, Michigan, United States (enrolling)
• Wayne State University Physician Group Dermatology — Detroit, Michigan, United States (enrolling)
• Revival Research Institute, Llc Troy — Troy, Michigan, United States (enrolling)
• Washington University — St Louis, Missouri, United States (enrolling)
• Boeson Research Missoula 2825 Fort Missoula Rd — Missoula, Montana, United States (enrolling)
• University of New Mexico Hospital — Albuquerque, New Mexico, United States (enrolling)
• Geisinger Medical Center — Danville, Pennsylvania, United States (enrolling)
• Bellaire Dermatology Associates Bda — Bellaire, Texas, United States (enrolling)
• Texas Dermatology Research Center — Dallas, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.